Kathryn Wood Cathie Wood's latest ARK operation analysis

Currently, Wood and her disruptive vision are facing a huge test. The flagship fund ArkinNovation ETF (ARKK) just recorded its worst weekly performance since February, falling 12.7% to its lowest level in more than a year. 6 of the company's 8 strategies recorded declines in 2021, of which the worst performer was $ARK Genomic Revolution ETF(ARKG.US)$ , a drop of 37%. ARKK once fell 4.8% at the opening of the New York market. At the close, ARKK recovered lost ground and rose 1.5%. The fund has fallen nearly 24% this year.

① The ARK series active ETF operated a total of 7 transactions on the same day, of which 5 stocks were bought and 2 stocks were sold.

② $ARK Fintech Innovation ETF(ARKF.US)$ und $ARK Innovation ETF(ARKK.US)$ Kakura $Signify Health(SGFY.US)$ It is a leading healthcare platform that leverages advanced analytics, technology, and a nationwide network of healthcare providers to create and support value-based payment programs.

3ARKK Kakura $Teladoc Health(TDOC.US)$ Teladoc is a tele-care company that provides on-demand health care via mobile devices, the Internet, video, and phone. The solution directly connects physicians, health care professionals, healthcare providers and users to provide a wide range of acute diagnoses, such as upper respiratory infections, urinary tract infections, sinusitis, skin diseases, anxiety, and smoking cessation conditions and cases.

④ ARKK sells $Editas Medicine(EDIT.US)$, Editas
Medicine is a genome-editing company. The company is treating genetic diseases by modifying causative genes.